alexa
Reach Us +1-217-403-9671
Challenges In SiRNA/ ShRNA Delivery And Development Of RNAi Therapeutics For Cancer | 8385
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Challenges in siRNA/ shRNA delivery and development of RNAi therapeutics for cancer

International Conference & Exhibition Bioequivalence and Bioavailability

Tathagata Dutta

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.1000001

Abstract
A lthough small interfering RNA (siRNA) treatment holds great promise for the treatment of cancers, the field has been held back by the availability of suitable delivery system. Unmodified, naked siRNAs are relatively unstable in blood and serum as they are rapidly degraded by endonuclease and exonucleases, thereby having very short in vivo half-life. The administered siRNA, should be suitably internalized by the target cell, must avoid endosomal uptake & errant siRNA compartmentalization for exerting gene silencing activity. Selection and formulation of siRNA with an appropriate biocompatible and possibly �genocompatible� delivery system is necessary for improving biological stability, targeted cell uptake, and pharmacokinetics of siRNA. Inappropriate selection of a delivery vector can thereby reduce gene-silencing activity and even enhance off-target effects. Delivery systems can also alter the pharmacokinetics of siRNA by altering their molecular and physical size so as to reduce excretion via the kidneys and thereby prolong in vivo half-life. Targeting to diseases cell is necessary for efficient gene silencing. Once inside the cell, siRNA has to escape compartmentalization into cell organelles such as endosomes and lysosomes, be intracellularly bioavailable, and interact with its intended mRNA targets in the cytosol to effect highly potent and sequence-specific gene-silencing activity. Strategies for delivering siRNA to specific tissue/organ in vivo following systemic administration involves hydrodynamic intravenous injection, cationic liposomes, cationic polymer and peptide based delivery systems, local in vivo delivery systems, etc. The success of RNAi therapeutics for cancer lies in formulating siRNA/shRNA involving a suitable delivery system, which can overcome these challenges
Biography
Top